319 related articles for article (PubMed ID: 23916525)
1. Efficacy and tolerability of lamotrigine in juvenile myoclonic epilepsy in adults: a prospective, unblinded randomized controlled trial.
Machado RA; García VF; Astencio AG; Cuartas VB
Seizure; 2013 Dec; 22(10):846-55. PubMed ID: 23916525
[TBL] [Abstract][Full Text] [Related]
2. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study.
Morris GL; Hammer AE; Kustra RP; Messenheimer JA
Epilepsy Behav; 2004 Aug; 5(4):509-12. PubMed ID: 15256187
[TBL] [Abstract][Full Text] [Related]
3. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
4. A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy.
Park KM; Kim SH; Nho SK; Shin KJ; Park J; Ha SY; Kim SE
J Clin Neurosci; 2013 Aug; 20(8):1079-82. PubMed ID: 23673144
[TBL] [Abstract][Full Text] [Related]
5. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Montouris G; Abou-Khalil B
Epilepsia; 2009 Sep; 50 Suppl 8():16-20. PubMed ID: 19702728
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Chowdhury A; Brodie MJ
Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554
[TBL] [Abstract][Full Text] [Related]
7. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy.
Prasad A; Kuzniecky RI; Knowlton RC; Welty TE; Martin RC; Mendez M; Faught RE
Arch Neurol; 2003 Aug; 60(8):1100-5. PubMed ID: 12925366
[TBL] [Abstract][Full Text] [Related]
8. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison.
Levisohn PM; Holland KD
Epilepsy Behav; 2007 Jun; 10(4):547-52. PubMed ID: 17482520
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy.
Fakhoury TA; Hammer AE; Vuong A; Messenheimer JA
Epilepsy Behav; 2004 Aug; 5(4):532-8. PubMed ID: 15256191
[TBL] [Abstract][Full Text] [Related]
11. [Juvenile myoclonic epilepsy with recurrent myoclonic status: efficacy of valproate].
Crespel A; Velizarova R; Genton P; Gélisse P
Therapie; 2009; 64(5):321-3. PubMed ID: 19863907
[TBL] [Abstract][Full Text] [Related]
12. Outcome of lamotrigine treatment in juvenile myoclonic epilepsy.
Bodenstein-Sachar H; Gandelman-Marton R; Ben-Zeev B; Chapman J; Blatt I
Acta Neurol Scand; 2011 Jul; 124(1):22-7. PubMed ID: 21208196
[TBL] [Abstract][Full Text] [Related]
13. [Exacerbation of tonicoclonic seizures in a juvenile myoclonic epileptic taking lamotrigine].
Maiga Y; Nogues B; Guillon B
Rev Neurol (Paris); 2006 Nov; 162(11):1125-7. PubMed ID: 17086150
[TBL] [Abstract][Full Text] [Related]
14. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.
Marson AG; Al-Kharusi AM; Alwaidh M; Appleton R; Baker GA; Chadwick DW; Cramp C; Cockerell OC; Cooper PN; Doughty J; Eaton B; Gamble C; Goulding PJ; Howell SJ; Hughes A; Jackson M; Jacoby A; Kellett M; Lawson GR; Leach JP; Nicolaides P; Roberts R; Shackley P; Shen J; Smith DF; Smith PE; Smith CT; Vanoli A; Williamson PR;
Lancet; 2007 Mar; 369(9566):1016-26. PubMed ID: 17382828
[TBL] [Abstract][Full Text] [Related]
15. Treatment of juvenile myoclonic epilepsy.
Auvin S
CNS Neurosci Ther; 2008; 14(3):227-33. PubMed ID: 18684236
[TBL] [Abstract][Full Text] [Related]
16. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate.
Calleja S; Salas-Puig J; Ribacoba R; Lahoz CH
Seizure; 2001 Sep; 10(6):424-7. PubMed ID: 11700996
[TBL] [Abstract][Full Text] [Related]
17. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy.
Specchio LM; Gambardella A; Giallonardo AT; Michelucci R; Specchio N; Boero G; La Neve A
Epilepsy Res; 2006 Sep; 71(1):32-9. PubMed ID: 16814521
[TBL] [Abstract][Full Text] [Related]
18. Exacerbation of juvenile myoclonic epilepsy with lamotrigine.
Biraben A; Allain H; Scarabin JM; Schück S; Edan G
Neurology; 2000 Dec; 55(11):1758. PubMed ID: 11113246
[No Abstract] [Full Text] [Related]
19. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.
Coppola G; Auricchio G; Federico R; Carotenuto M; Pascotto A
Epilepsia; 2004 Sep; 45(9):1049-53. PubMed ID: 15329068
[TBL] [Abstract][Full Text] [Related]
20. Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy.
Stephen LJ; Sills GJ; Leach JP; Butler E; Parker P; Hitiris N; Leach VM; Wilson EA; Brodie MJ
Epilepsy Res; 2007 Jul; 75(2-3):122-9. PubMed ID: 17553671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
